A federal judge rejected Regeneron's request for a preliminary injunction against Amgen in its lawsuit for Eylea's biosimilar ...

Regeneron Pharmaceuticals is a leading biotech firm with a strong portfolio. Click here to know what justifies a Buy rating ...

Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...

Regeneron sued Amgen in January, alleging that it was developing a biosimilar that violated key patent protections for Eylea.

Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

Jefferies analyst Akash Tewari maintained a Buy rating on Regeneron (REGN – Research Report) yesterday and set a price target of ...

In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...

AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and ...

The court's decision comes after a West Virginia judge previously denied Regeneron's request for a preliminary injunction against Amgen's biosimilar version of Eylea. Regeneron had filed an ...